
Merus Labs International Inc. (TSE:MSL – Free Report) (NASDAQ:MSLI) – Investment analysts at HC Wainwright lifted their Q2 2026 earnings per share estimates for Merus Labs International in a research note issued to investors on Monday, May 18th. HC Wainwright analyst A. He now anticipates that the specialty pharmaceutical company will earn ($0.49) per share for the quarter, up from their previous forecast of ($0.50). HC Wainwright also issued estimates for Merus Labs International’s Q3 2026 earnings at ($0.49) EPS, Q4 2026 earnings at ($0.49) EPS, FY2026 earnings at ($2.20) EPS, Q1 2027 earnings at ($0.54) EPS, Q2 2027 earnings at ($0.58) EPS, Q3 2027 earnings at ($0.63) EPS, Q4 2027 earnings at ($0.67) EPS, FY2027 earnings at ($2.42) EPS, FY2028 earnings at ($2.57) EPS and FY2029 earnings at ($1.59) EPS.
Other analysts have also issued research reports about the company. Guggenheim raised Merus Labs International to a “strong-buy” rating in a research note on Tuesday, April 28th. Leerink Partners upgraded Merus Labs International to a “strong-buy” rating in a research report on Monday, April 6th. Finally, Cantor Fitzgerald upgraded Merus Labs International to a “strong-buy” rating in a research report on Wednesday, March 11th. Three research analysts have rated the stock with a Strong Buy rating, According to MarketBeat, the stock currently has an average rating of “Strong Buy”.
Merus Labs International Price Performance
Merus Labs International has a 52 week low of C$0.95 and a 52 week high of C$1.76.
About Merus Labs International
Merus Labs International Inc is a specialty pharmaceutical company. The Company is engaged in the acquisition and licensing of branded prescription pharmaceutical products. The Company’s products include Elantan, Isoket, Deponit, Sintrom, Emselex/Enablex, Surgestone, Provames, Speciafoldine, Tredemine, Salagen, Estraderm MX and Vancocin. Elantan are tablets or capsules that belong to a group of medicines called organic nitrates. Isoket belongs to a group of medicines called organic nitrates. Deponit belongs to a group of medicines called nitrates.
Featured Stories
- Five stocks we like better than Merus Labs International
- HIVE Weaponizes Power for an AI Pivot
- A Deep Dive Into NVIDIA’s Latest Portfolio Moves
- Brady Corp Wires Up a Massive AI-Powered Breakout
- Why Home Depot’s Sell-Off Could Become a Huge Opportunity
Receive News & Ratings for Merus Labs International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merus Labs International and related companies with MarketBeat.com's FREE daily email newsletter.
